Overview of recent advances in metastatic triple negative breast cancer.
Issue Date
2021-03Keywords
BREAST CANCERIMMUNOTHERAPY
Poly (adenosine diphosphate-ribose) polymerase inhibitors
triple negative breast cancer
Metadata
Show full item recordJournal
World journal of clinical oncologyDOI
10.5306/wjco.v12.i3.164PubMed ID
33767972Abstract
Metastatic triple negative breast cancer (TNBC) has an aggressive phenotype with a predilection for visceral organs and brain. Best responses to chemotherapy are predominately in the first line. Recent studies have demonstrated improved progression free survival with the combination of atezolizumab/pembrolizumab and chemotherapy in programmed death-ligand 1 positive metastatic TNBC. However, a recent trial in a similar population showed no benefit for atezoli-zumab and paclitaxel which led to a Food and Drug Administration alert. Two phase III trials (OLYMPIAD and BROCADE3) demonstrated a benefit in progression free survival (PFS) but not overall survival in patients with BRCA-associated metastatic TNBC treated with Olaparib or Talazoparib respectively. For those treated with Talazoparib, the time to deterioration in health related-quality of life was also longer compared to chemotherapy. The BROCADE3 trial demonstrated that the combination of a platinum and veliparib increased PFS in first-line metastatic TNBC but at the cost of increased toxicity. There are no head-to-head comparisons of a poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPi) and platinums. There are unanswered questions regarding the role of PARPi maintenance after platinum therapy as is standard of care in BRCA-associated ovarian cancer. Other areas of therapeutic interest include targeting aberrations in the phosphoinositide 3-kinase pathway, protein kinase B, mammalian target of rapamycin or utilising antibody drug conjugates. This review focusses on recent and emerging therapeutic options in metastatic TNBC. We searched PubMed, clinicaltrials.gov and recent international meetings from American Society of Clinical Oncology, San Antonio Breast Cancer Conference and the European Society of Medical Oncology.Item Type
ArticleLanguage
enISSN
2218-4333ae974a485f413a2113503eed53cd6c53
10.5306/wjco.v12.i3.164
Scopus Count
Collections
Related articles
- Poly(ADP-ribose) polymerase inhibitors in the treatment landscape of triple-negative breast cancer (TNBC).
- Authors: El Gazzar WB, Albakri KA, Hasan H, Badr AM, Farag AA, Saleh OM
- Issue date: 2023 Sep
- Update on PARP Inhibitors in Breast Cancer.
- Authors: Zimmer AS, Gillard M, Lipkowitz S, Lee JM
- Issue date: 2018 Apr 11
- Emerging therapeutic modalities of PARP inhibitors in breast cancer.
- Authors: Wang X, Shi Y, Huang D, Guan X
- Issue date: 2018 Jul
- Management of human epidermal growth factor receptor 2-negative metastatic breast cancer: Role of poly adenosine diphosphate (ADP-ribose) polymerase inhibitors.
- Authors: Vaid AK, Deshmukh C, Rohatgi N, Ghosh J
- Issue date: 2022 Mar
- Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer.
- Authors: Cipriano É, Mesquita A
- Issue date: 2021